Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Concomitant Bexsero and Menveo in Healthy Infants
NCT02106390Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal infection (3 arms), sponsored by GSK. Primary endpoints: Human Serum Bactericidal Activity Geometric Mean Titers Against Serogroup B Indicator Strains at Day 331 and Human Serum Bactericidal Activity Geometric Mean Titers Against Serogroups A, C, W-135 and Y at Day 331. Started Jun 2014; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT02106390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106390.